Precision Medicine


Beijing Jing Meng Precision Medical Institute

 

Beijing Jingmeng Precision Medical Institute was initiated by Beijing Jing Meng High-Tech Stem Cell Technology, Zhongwei Capital, Zhongfu Jiahua and Zhongguancun Translational Medical Technology in 2017.

The company is mainly engaged in genetic testing, cell and molecular clinical testing, pathological analysis, medical imaging, personalized targeted precision treatment, personalized tumor vaccine, medical big data analysis, medical artificial intelligence and other fields, forming a production and research covering the domestic market. The development pattern of integrated group-based industries will gradually increase the development and market share of the international market. Strengthening operational capacity and system construction, making it a world-class demonstration institution for precision medical industrialization, and becoming an important supporting unit for the precision medicine industry and great health.

The institute now has a number of advanced high-throughput gene sequencing, flow cell sorting instrument, ultracentrifuge, fluorescence quantitative PCR instrument, nucleic acid interrupter, automatic microchip electrophoresis instrument, rapid cell analysis instrument, protein two-dimensional electrophoresis, etc. imported equipment and equipment can carry out various types of genetic testing projects.

Beijing Jing Meng Precision Medical Institute had signed agreement with China Yong Travel to build research Lab in Hainan Island and provide medical travel, anti-aging and healthcare improvement services. Also, we will set up two clinics in Beijing for the translational medicine meaning from research lab works to clinic services. It will be our healthcare improvement in the future combines with Research, Education & Training and Clinical Application.

 
 
Precision Medicine_application_Application_Jing-Meng Stem Cell

Precision Medicine


Beijing Jing Meng Precision Medical Institute

 

Beijing Jingmeng Precision Medical Institute was initiated by Beijing Jing Meng High-Tech Stem Cell Technology, Zhongwei Capital, Zhongfu Jiahua and Zhongguancun Translational Medical Technology in 2017.

The company is mainly engaged in genetic testing, cell and molecular clinical testing, pathological analysis, medical imaging, personalized targeted precision treatment, personalized tumor vaccine, medical big data analysis, medical artificial intelligence and other fields, forming a production and research covering the domestic market. The development pattern of integrated group-based industries will gradually increase the development and market share of the international market. Strengthening operational capacity and system construction, making it a world-class demonstration institution for precision medical industrialization, and becoming an important supporting unit for the precision medicine industry and great health.

The institute now has a number of advanced high-throughput gene sequencing, flow cell sorting instrument, ultracentrifuge, fluorescence quantitative PCR instrument, nucleic acid interrupter, automatic microchip electrophoresis instrument, rapid cell analysis instrument, protein two-dimensional electrophoresis, etc. imported equipment and equipment can carry out various types of genetic testing projects.

Beijing Jing Meng Precision Medical Institute had signed agreement with China Yong Travel to build research Lab in Hainan Island and provide medical travel, anti-aging and healthcare improvement services. Also, we will set up two clinics in Beijing for the translational medicine meaning from research lab works to clinic services. It will be our healthcare improvement in the future combines with Research, Education & Training and Clinical Application.